Global HealthPharmaceutical Regulations in Japan

Trust and Ethics

We at JPMA follow our established Code of Practice.

The true nature of a medicine cannot be determined solely from its appearance. In order to understand both the effects and possible side effects of a medicine, provision of the correct information for use is required: without this the product cannot function effectively as a medicine. Provision of information which lacks appropriate balance of effects and side effects, or inappropriate sales activities, not only promotes the incorrect use of medicines and interferes with optimal treatments for patients, but may also cause harmful effects to patients' health. Therefore, pharmaceutical companies bear a solemn responsibility to provide accurate, fair, and scientifically grounded information for their products, so that the appropriate use of medicines can be facilitated. This responsibility is universal, and applies in both developed and developing countries.

In recent years, the demand for pharmaceutical companies regarding ethics and transparency from stakeholders has increased. R&D-based pharmaceutical companies need to show that they operate according to high ethical standards at all times, thereby earning a higher degree of trust from society for them to accomplish their mission. When engaging in promotional activities for pharmaceuticals or interacting with medical professionals, researchers, patient groups and other stakeholders, JPMA member companies adhere to the "JPMA Code of Practice", which itself conforms to the "IFPMA Code of Practice" international standard. This is to ensure patients receive ethical, optimal treatment with their best interests in mind.

In addition, JPMA member companies develop their own guidelines in line with the following JPMA publications: "Transparency guidelines for relationships related to cooperate activities and medical institutions" and "Transparency guidelines for relationships related to cooperate activities and patient groups". Over the two-year period 2013-2014, JPMA member companies introduced information disclosure practices which comply with these revised guidelines.

JPMA, as a member of the IFPMA Code Compliance Network, actively participates in promoting the further global diffusion of the IFPMA Code. JPMA also participated in development of the "Mexico City Principles", a voluntary business code of ethics in the pharmaceutical industry approved at the APEC ministerial meeting in 2011. JPMA works to promote ethical business practices for the promotion and sale of medicines based on these principles, into developed countries and developing countries, and into R&D-based pharmaceutical companies and other pharmaceutical companies, regardless of company size.

JPMA contributes to patient health through establishing high ethical standards in the pharmaceuticals industry and disseminating them on a global basis.

Page Top

  • Office of Pharmaceutical Industry Research(OPIR)
  • Global Health
  • Stop AMR
  • APAC